SELLAS Life Sciences shares fell on October 28, 2026, after the company said its Phase 3 REGAL trial of cancer treatment candidate galinpepimut-S had reached the milestone needed to begin its final analysis. Preliminary topline results are expected in the fourth quarter.
REGAL trial reaches survival milestone
SELLAS said in its REGAL trial announcement that the study had reached its pre-specified 80th event, meaning the 80th death recorded for the event-driven analysis. The milestone triggers the final analysis; it does not itself indicate whether the treatment improved survival.
The company plans to lock the trial database, unblind the study data and statistically analyze the primary endpoint. It expects to announce preliminary topline results this quarter, after that analysis is completed.
What the study is testing
The randomized trial is evaluating galinpepimut-S, or GPS, as a potential maintenance therapy for patients with acute myeloid leukemia who have achieved a second complete remission. Its primary endpoint is overall survival; secondary endpoints include leukemia-free survival and other clinical outcomes.
GPS targets the WT1 protein, which is present in a range of tumors. SELLAS shares declined following the announcement, although the available information does not establish what caused the move or specify its size.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
Comments
Be respectful. No spam, impersonation or private credentials. Ordinary posts and comments appear immediately; suspicious links are held for review.
Please wait…